So far, CKAP2L has only been studied in a few types of tumors and has been shown to be highly expressed and to promote tumor progression in prostate cancer5, glioblastoma6, oesophageal squamous cell carcinoma7, non-small cell lung cancer8 and breast cancer9, where it is a potential prognostic biomarker. This evidence concerns the gene CKAP2L and neoplasm.